Apimeds Pharmaceuticals US, Inc. Files Form 8-K: Delay in Annual Report Filing and Potential NYSE American Non-Compliance Notice

Key Highlights:

• Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) announced via Form 8-K that it will not be able to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, within the prescribed deadline.
• The company had previously filed a Notification of Late Filing (Form 12b-25) on March 31, 2026, indicating it needed additional time to complete its financial statements and for its independent auditor to finish the audit.
• Apimeds now expects it will not be able to file the Form 10-K within the fifteen-day extension period allowed under Rule 12b-25.

Details and Analysis:

• The delay in filing is primarily due to:
  • Continued preparation and finalization of financial statements for Q4 and the full year 2025.
  • Additional time needed by the company’s independent registered public accounting firm to complete audit procedures.
• As a result, Apimeds expects to receive a notice from NYSE American indicating non-compliance with continued listing requirements due to the late filing.
• Such a notice would typically allow Apimeds to submit a plan to regain compliance with NYSE American’s listing standards.
• The company is working diligently to finalize its Form 10-K and currently expects to file by April 30, 2026, but cautions that there is no assurance it will meet this date.
• The Form 8-K is signed by Erick Frim, Chief Financial Officer, dated April 16, 2026.

Potential Price-Sensitive Information for Shareholders:

• Risk of NYSE American Non-Compliance: The anticipated receipt of a non-compliance notice from NYSE American is highly significant. Failure to comply with exchange requirements could potentially lead to trading halts, delisting, or negative investor sentiment.
• Uncertainty in Financial Reporting: The inability to file audited financial statements on time may raise concerns about internal controls, financial health, or operational issues. This uncertainty could impact investor confidence and share price volatility.
• Emerging Growth Company: Apimeds is classified as an “emerging growth company,” which means it may be subject to reduced disclosure requirements and may elect not to use the extended transition period for new accounting standards. However, the company has not elected to use the extended transition period, indicating it intends to comply with new standards as they become effective.
• Common Stock Details: The company’s common stock (par value \$0.01 per share) trades under the symbol “APUS” on NYSE American.

Additional Information:

• The company’s principal office is located at 100 Matawan Rd, Suite 325, Matawan, NJ 07747. Business phone: 848-201-5010.
• There were no written communications pursuant to Rule 425, soliciting materials under Rule 14a-12, or pre-commencement tender offers under Rules 14d-2(b) or 13e-4(c) included in this filing.

Takeaway for Investors:

• The delay in filing audited financial statements and the expected NYSE American non-compliance notice are material events that could impact the stock price of APUS. Investors should monitor further announcements for the actual filing of the Form 10-K, the response to any compliance notice, and any subsequent action by NYSE American.
• Uncertainty regarding financial reporting and exchange compliance often leads to increased volatility and risk. Shareholders are strongly encouraged to review any subsequent filings and company communications for updates.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. The information summarized herein is based on public SEC filings and may be subject to change. Investors should conduct their own due diligence and consult with financial professionals before making any investment decisions regarding Apimeds Pharmaceuticals US, Inc. or its securities.

View Apimeds Pharmaceuticals US, Inc. Historical chart here